ALFA FinderBSE filing, NSE: M3GLOBAL. Summary written from the filing by ALFA Finder's alert engine.
Niyogin Fintech Ltd: key numbers
- Share price
- ₹45.50
- Market cap
- ₹505.0 Cr
- Revenue (annual)
- ₹286.9 Cr
- Net profit (annual)
- ₹-0.47 Cr
- P/E (TTM)
- -302.0×Sector 20.8×
- Promoter holding
- 39.50%+0.00% QoQ
- FII holding
- 19.53%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Niyogin Fintech Ltd
All →Niyogin Fintech Investor Presentation: Key Takeaways
Q2 FY27 consolidated net revenue ₹23.9 Cr (+8% QoQ, -8% YoY) with PAT loss ₹(3.7) Cr. iServeU recovering; NBFC AUM fell 19% QoQ to ₹270 Cr.
Niyogin Fintech Management Change
Niyogin Fintech redesignated Ronak Shah from Deputy CFO to Interim CFO, effective 13 November 2026. The change follows the 12 November 2026 board meeting.
Niyogin Fintech Employee Stock Options
Niyogin Fintech allotted 10,000 equity shares to an employee exercising options under its 2018 ESOP plan. The company states the allotment is not material.
Niyogin Fintech Q2 FY27 Results: Net Loss of ₹3.7 Cr
Niyogin Fintech Ltd reported revenue from operations of ₹63.8 Cr (-9.0% YoY) and a net loss of ₹3.7 Cr for Q2 FY27.
- Key figure
- Net loss ₹3.7 Cr
Niyogin Fintech Board Meeting Date
Niyogin Fintech scheduled a board meeting on 12 November 2026 to consider unaudited quarterly results. The trading window stays closed until 48 hours after the results.
Niyogin Fintech Debt & Borrowing: ₹0.27 Cr
Niyogin Fintech paid Rs.27 lakh interest on its 12.60% Niyogin3 2027 NCDs on the due date, November 5, 2026. No delay was reported.
- Value
- ₹0.27 Cr
Other results update announcements
All →Prakash Pipes Results Update
Prakash Pipes reported Q2 FY27 net sales of ₹259 crores, up 43%, with PAT rising 72% to ₹16 crores. Half-year net sales reached ₹501 crores.
Gaudium IVF And Women Health Results Update
Gaudium IVF reported Q2 FY27 revenue of ₹37.4 crore, up 17.9% YoY, with H1 revenue at ₹56.8 crore. Two new IVF hubs commenced operations during the quarter.
Systematix Corporate Services Results Update
Systematix's Q2 FY27 adjusted revenue rose 102% QoQ to ₹56.04 crore, with PAT of ₹13.13 crore. Year-on-year revenue was flat, while H1 PAT fell to ₹8.24 crore.
TARC Results Update
TARC reported H1 FY2027 total income of ₹352.78 crore and PAT of ₹27 crore. Q2 PAT was ₹4.05 crore, versus a loss in Q2 FY2026.
Balaxi Pharmaceuticals Results Update
Balaxi Pharmaceuticals issued a press release on Q2 FY27 results, with revenue up 45% and PAT up 450% year-on-year. EBITDA rose 338% to ₹512.07 lakh.
Q-Line Biotech Results Update
Q-Line Biotech's H1 FY27 revenue rose 5.83% while EBITDA grew 10.02%, but PAT fell 8.06%. The release also covers a proposed 70% stake acquisition in Heidelco.